Furthermore, in a preclinical study, botensilimab, an Fc-enhanced anti-CTLA-4 antibody, exhibited effectiveness comparable to or superior to conventional chemotherapeutics, such as gemcitabine, nab-paclitaxel, and cisplatin, controlling 7 of 10 tumor cells in combination with chemotherapy [213]. The gene discussed is CTLA4; the disease is neoplasm.